BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Essential Thrombocythemia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Essential Thrombocyth
 emia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06079879-2890@assetmemo.bio
DTSTAMP:20261121T005412Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06079879)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: A St
 udy of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (
 BAT) in Participants With Essential Thrombocythemia and an Inadequate Resp
 onse or Intolerance of Hydroxyurea (MK-3543-006)\nEstimated primary comple
 tion: 14 July 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 omedemstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06079879
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456346-2890@assetmemo.bio
DTSTAMP:20261121T005412Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06456346)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: Bome
 demstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)\nEstima
 ted primary completion: 28 September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bomedemstat#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06456346
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623200-10795@assetmemo.bio
DTSTAMP:20261121T005412Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:INCA033989: Phase 3 readout est. (NCT07623200)
DESCRIPTION:INCA033989\, phase 3\, Essential Thrombocythemia.\nStudy: A Pha
 se 3 Study of INCA033989 Versus Best Available Therapy in Participants Wit
 h Essential Thrombocythemia\nEstimated primary completion: 15 June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/inca033989#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07623200
URL:https://assetmemo.bio/drug/inca033989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351631-2890@assetmemo.bio
DTSTAMP:20261121T005412Z
DTSTART;VALUE=DATE:20341204
DTEND;VALUE=DATE:20341205
SUMMARY:Bomedemstat: Phase 3 readout est. (NCT06351631)
DESCRIPTION:Bomedemstat\, phase 3\, Essential Thrombocythemia.\nStudy: A St
 udy to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)\nEstimate
 d primary completion: 4 December 2034. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bomedemstat#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06351631
URL:https://assetmemo.bio/drug/bomedemstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
